ClinicalTrials.gg

Program

Foritinib Succinate

In Fosun Pharma's pipeline, ALK. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Fosun Pharma.

Furthest: phase 2, since Jan 15, 20201 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma11 open or runningphase 2since Jan 15, 2020Jan 15, 2020none ahead
  • Named in Fosun Pharma’s own pipeline as SAF-189s (ALK), phase 4, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2020First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04237805 · 280 planned · China

TargetBeta

“ALK”the company's pipeline, read by Claude · source

Other programs on ALK

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431
lorlatinibrulePfizerphase 420
gilteritinibruleAstellas Pharmaphase 320
ensartinibruleBetta Pharmaceuticalsphase 312
repotrectinibruleBristol-Myers Squibbphase 39
neladalkibGlaxoSmithKlinephase 32
ALK Molecular Glue Degrader TRI-611ruletriana-biomedicines-incphase 21
AQUA07Hoffmann-La Rochephase 11
SIM0518ruleSimcere Pharmaceutical Groupphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04237805Carcinoma, Non-Small-Cell Lung · China2RecruitingDec 31, 2022280

How it is read

Names in the registry

  • “SAF-189s”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.